Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Specificity and functional humoral immune responses induced by the VBI-1501A eVLP HCMV gB vaccine compared to the gB/MF59 vaccine.Human vaccines & immunotherapeutics · 2025
   Article
2. Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV's Immunological Achilles' Heel.Vaccines · 2025
   Review
3. Genomic and geographical structure of human cytomegalovirus.Proceedings of the National Academy of Sciences of the United States of America · 2023
   Article
4. Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021.Transplant infectious disease : an official journal of the Transplantation Society · 2022
   Review
5. Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022
   Review
6. Insight for Immunotherapy of HCMV Infection.International journal of biological sciences · 2021
   Review
7. Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity.PLoS pathogens · 2020
   Article
8. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.Science translational medicine · 2020
   Article
9. Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection.Vaccines · 2020
   Article
10. Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development.Vaccines · 2020
    Review
11. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.Journal of virology · 2020
    Article
12. Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.Viruses · 2019
    Review
13. Exploring the N-Glycosylation Profile of Glycoprotein B from Human Cytomegalovirus Expressed in CHO andInternational journal of molecular sciences · 2019
    Article
14. The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation.Vaccines · 2019
    Review
15. HCMV Envelope Glycoprotein Diversity Demystified.Frontiers in microbiology · 2019
    Article

Corrections and comments

• Comment on
  Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.2018
• Comment on
  HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.2018

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as